Intervacc is trading at €0.04, down 21.09%, in a move most consistent with biotech-sector weakness.
- No company-specific announcement dated October 8 or 9 was found; its latest listed release was September 15.
- Supplied sector context shows XBI down 2.04%, with no clear sector-wide catalyst.
- Elevated yields and geopolitical tensions may have added to broader risk-off pressure, but no direct company catalyst is established.